M
Mariella Soraru
Publications - 14
Citations - 296
Mariella Soraru is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 287 citations.
Papers
More filters
Journal ArticleDOI
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
Melina Verso,Giancarlo Agnelli,Sergio Bertoglio,Franco C. Di Somma,Francesco Paoletti,Walter Ageno,Mario Bazzan,P. Parise,Roberto Quintavalla,Emanuele Naglieri,Armando Santoro,Davide Imberti,Mariella Soraru,Stefano Mosca +13 more
TL;DR: No difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo, and the dose of enoxAParin used in this study proved to be safe.
Journal ArticleDOI
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
Sara Elena Rebuzzi,Alessio Signori,Marco Stellato,Daniele Santini,Marco Maruzzo,Ugo De Giorgi,Paolo Pederzoli,Luca Galli,Paolo Andrea Zucali,Emanuela Fantinel,Claudia Carella,Giuseppe Procopio,Michele Milella,Francesco Boccardo,Lucia Fratino,Roberto Sabbatini,Riccardo Ricotta,Stefano Panni,Francesco Massari,Mariella Soraru,Matteo Santoni,Alessio Cortellini,Veronica Prati,Hector Soto Parra,Francesco Atzori,Marilena Di Napoli,Orazio Caffo,Marco Messina,Franco Morelli,Giuseppe Prati,Franco Nolè,Francesca Vignani,Alessia Cavo,Giandomenico Roviello,M.A. Llaja Obispo,Camillo Porta,Sebastiano Buti,Giuseppe Fornarini,Giuseppe Luigi Banna +38 more
TL;DR: Early neutrophils and NLR Δ may represent new dynamic prognostic factors with clinical utility for on-treatment decisions and are associated with disease progression in patients with baseline lower lymphocytes.
Journal ArticleDOI
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
Sara Elena Rebuzzi,Alessio Signori,Giuseppe Luigi Banna,A. Gandini,Giuseppe Fornarini,Alessandra Damassi,Marco Maruzzo,Ugo De Giorgi,Umberto Basso,Silvia Chiellino,Luca Galli,Paolo Andrea Zucali,Emanuela Fantinel,Emanuele Naglieri,Giuseppe Procopio,Michele Milella,Francesco Boccardo,Lucia Fratino,Stefania Pipitone,Riccardo Ricotta,Stefano Panni,Veronica Mollica,Mariella Soraru,Matteo Santoni,Alessio Cortellini,Veronica Prati,Hector Soto Parra,Daniele Santini,Francesco Atzori,Marilena Di Napoli,Orazio Caffo,Marco Messina,Franco Morelli,Giuseppe Prati,Franco Nolè,Francesca Vignani,Alessia Cavo,Giandomenico Roviello,Pasquale Rescigno,Sebastiano Buti +39 more
TL;DR: In this paper , the authors investigated the role of nephrectomy in the prognosis of patients with localized and selected metastatic renal cell carcinoma (mRCC) receiving nivolumab.
Journal ArticleDOI
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Marco Maruzzo,Francesco Pierantoni,Alberto Bortolami,Dario Palleschi,Andrea Zivi,Maurizio Nicodemo,Donata Sartori,Rocco De Vivo,Fable Zustovich,Davide Bimbatti,Davide Pastorelli,Giuseppe Vultaggio,Mariella Soraru,Melissa Ballestrin,Caterina Modonesi,Paola Randisi,Carmen Barile,G. Perri,Umberto Basso,Vittorina Zagonel +19 more
TL;DR: In this article , the authors conducted an analysis of oncological outcomes in patients treated in the Veneto Region (Italy), studying different sequences of TKI-nivolumab-cabozantininib or TKI -caboostinib-nivo-umab in a publicly funded healthcare system.
Journal ArticleDOI
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study.
Marco Stellato,Sebastiano Buti,Marco Maruzzo,G Fotia,Mariella Soraru,Maria Bassanelli,Brigida Anna Maiorano,Francesco Grillone,Luca Galli,Roberto Filippi,Martina Fanelli,Michele Dionese,Michele Maffezzoli,Bruno Vincenzi,Giuseppe Procopio,Elena Verzoni +15 more
TL;DR: In this article , the authors describe RCC patients with peritoneal metastases (PM) treated with TKI and IO-TKI and show that TKI-IO as first line treatment, compared to TKI monotherapy, and TKI as second line treatment compared to IO, are more active treatment for these patients with dismal prognosis.